Join us for a ground-breaking and insightful forum on inhaled and nasal biologics or inhaled vaccine development: Two days of cutting-edge talks and networking opportunities with leaders in this complex area of drug and vaccine development.

3rd Annual Inhaled & Nasal Biologics/DNA Forum
26-27th September 2024 | Cambridge, UK 
 

We are delighted to announce that we are hosting the 3rd edition of the Annual Inhaled and Nasal Biologics/DNA Forum in September 2024. We invite you to join two days of cutting-edge talks and networking opportunities with leaders in this complex area of drug productor and inhaled vaccines development.

Biologics and nucleotide-based therapeutics have gained increasing importance in the last decade. Pulmonary and intranasal delivery of these presents a compelling, non-invasive alternative to traditional parenteral methods, offering potential for both local respiratory and systemic treatments across a variety of diseases and indications. However, biologics, mRNA, nucleotide-based therapeutics and vaccines present unique challenges for respiratory administration and whilst there can be many ways to design a product, the developer needs to balance, amongst many other things, product performance, manufacturability, regulatory risk, and commercial elements. 

During this 3rd edition, the conference promises to provide a platform for discussing the latest research and optimal strategies for pulmonary and intranasal biologic/DNA drug development. With renowned industry leaders who will share their insight and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don't miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics. 

Secure your place today -  registration is live.

 MEET OUR SPEAKERS

We will be releasing more news of our esteemed speakers over the coming weeks. Be sure to bookmark this page and follow us on LinkedIn to stay updated with the latest developments. 

KEYNOTE:
Dr Jenny Lam, Associate Professor in Pharmaceutics at the UCL School of Pharmacy

We are thrilled to announce that Dr Jenny Lam, Associate Professor in Pharmaceutics at the UCL School of Pharmacy, will be the keynote speaker for the third Annual Inhaled and Nasal Biologics/DNA Forum 2024. 

Dr Jenny Lam is a leading expert in novel respiratory delivery systems at the UCL School of Pharmacy, one of the world’s leading pharmacy schools. Dr Lam will present on the theme of ‘Alternative to LNPs – development of peptide-based RNA delivery systems for pulmonary delivery’, setting the stage for thought-provoking exchanges throughout this groundbreaking industry event. 

Portrait photo of Dr Jenny Lam  Associate Professor in Pharmaceutics at the UCL School of Pharmacy
Dr Jenny Lam

Associate Professor in Pharmaceutics at the UCL School of Pharmacy

Keynote Talk: Alternative to LNPs – development of peptide-based RNA delivery systems for pulmonary delivery

Dr Lam’s research is focused on the development of novel delivery systems for RNAs and biologics, with a special interest in using particle engineering methods to produce dry powder aerosols for lung delivery, targeting various respiratory diseases and infections. She has published over 90 peer-reviewed articles and filed a number of patent applications on pulmonary drug delivery systems. In 2020, she was awarded the DDL Emerging Scientist Award which recognised her significant accomplishment and innovation in inhalation science. Additionally, Dr Lam recently co-edited ‘Respiratory Delivery of Biologics, Nucleic Acids and Vaccines’, a comprehensive review of pulmonary delivery of macromolecules and biologics.

 Prof Dr Regina Scherliess
Prof Dr. Regina Scherließ

Director, Department of Pharmaceutics and Biopharmaceutics, Kiel University

Talk Title: Nasal delivery of vaccines - not as easy as expected

Prof. Dr. Regina Scherließ is a professor for Pharmaceutics and Biopharmaceutics, vice-dean for research of the Faculty of Natural Sciences at Kiel University (since 2022) and chair of the Department of Pharmaceutics at Kiel University, Germany. As such she leads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics at Kiel University. She is a pharmacist and received her Dr. rer. nat. (doctor of natural sciences) in 2008 for a work on “Formulation of inhalation combination products by co-precipitation”. In 2015 she finished her “habilitation” working on “Mucosal vaccination via the respiratory tract”. During her academic education she had research stays in Denmark, the US, New Zealand and Australia. She also received several young researcher awards including The Pat Burnell New Investigator Award 2010 of the Aerosol Society and is member of the DDL scientific committee (since 2015). She also is member of the board of the priority research area KiNSIS (Kiel Nano Interface and Surface Sciences) at Kiel University (since 2020). Her research interests include disperse systems and nanoparticles, stabilisation of biomolecules and particle engineering in spray drying, and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery. She is a co-founder of the Nasal Research Focus Group, a research consortium from academia and industry focusing on nasal drug delivery.


AGENDA

Wednesday, September 25th 2024 - Networking
Intertek Laboratory Tour (optional), Intertek Melbourn, Cambridgeshire, 2 pm
Networking drinks reception, Hinxton Hall, 5.30 pm

Thursday, 26th September 2024 - Day 1 of Conference
Conference Session & Panel Discussion
Networking Drinks 5:30 pm & Evening: Conference Dinner

Friday, 27th September 2024 - Day 2 of Conference
Conference Session & Panel Discussion

 

REGISTRATION

The registration fee per attendee is shown below. This includes the conference registration, accommodation at Hinxton Hall if required, the conference dinner and networking drinks.

Rate Incl. 2 nights' accommodation Incl. 1 night accommodation No accommodation required
Early Bird Rate (until 31 May 2024) £499 £449 £399
Standard Rate (from 1 June 2024) £549 £499 £449



LOCATION 

Hinxton Hall, Cambridge, UK

Set within a one-hundred-acre estate bordering the River Cam, Hinxton Hall Conference Centre is located on the Wellcome Genome Campus, alongside research institutions that are at the forefront of the genomics revolution.

Hinxton Hall is 25 minutes from the centre of Cambridge, and a mere 60 minutes from London and accessible from Heathrow, Luton and Gatwick airports and is only 20 minutes from London Stansted Airport. The hall is easily accessible from the M11. For GPS please use: CB10 1SA.

The Intertek team will book accommodation on your behalf if you indicate that you require a room during registration. 


QUESTIONS? Please contact us: 
T: UK +44 (0)1763 261 648     |     E: inhaled.biologics@intertek.com

Follow us on LinkedIn #INBDF 

 
Meet our 2023 Speakers: Inhaled & Nasal Biologics/DNA Annual Forum

Intertek Melbourn

GMP Pharmaceutical Analysis and Formulation Expertise

Intertek Melbourn
Saxon Way, Melbourn
Herts, SG8 6DN 
UK

Recent News:
Laboratory Expansion for Specialist OINDP Development for Biologics